Physician profile
Mathew Lonberg
NPI 1235186065
$7,910.15
in general payments reported to CMS, 2019-2025
57 companies · $952 in 2025
The $952 reported for 2025 was less than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,197 · 2020: $1,074 · 2021: $255 · 2022: $545 · 2023: $676 · 2024: $1,212 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,555.70 |
| Education | $283.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,006.86 | 2019-2025 | |
| Janssen Biotech, INC. | $651.69 | 2019-2025 | Erleada, Rybrevant, Tecvayli |
| Pfizer INC. | $632.55 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $598.74 | 2019-2025 | Opdivo, Eliquis |
| Astrazeneca Pharmaceuticals LP | $456.58 | 2019-2025 | Imfinzi, Enhertu |
| Amgen INC. | $409.34 | 2019-2020 | |
| Genentech USA, INC. | $408.46 | 2019-2023 | Venclexta |
| Merck Sharp & Dohme LLC | $275.72 | 2019-2025 | Keytruda, Lynparza |
| Ipsen Biopharmaceuticals, INC | $248.94 | 2019-2024 | Tazverik, Onivyde |
| Mirati Therapeutics, INC. | $215.72 | 2023-2024 | Krazati |
| Eisai INC. | $183.35 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.55 | 2019-2022 | |
| Daiichi Sankyo INC. | $173.52 | 2019-2025 | Enhertu |
| Pharmacyclics LLC, An Abbvie Company | $159.95 | 2019-2023 | Imbruvica, Epkinly |
| Celgene Corporation | $157.93 | 2019-2024 | Reblozyl |
Show all 56 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Lonberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.